Comparison of Mometazon Furoate to Cetirizin for Symptom Severity Control and QOL in Allergic Rhinitis

Abstract

Objectives:

Evaluate and compare nasal symptom scores and quality of life (QOL) findings in allergic rhinitis patients.

Methods:

A total of 426 adult allergic rhinitis patients’ medical records were evaluated retrospectively. Group A consisted of 188 patients and received mometasone furoate nasal spray (100 mcg daily/nostril). Group B consisted of 238 patients receiving cetirizine (10 mg oral/daily) for 30 days. Nasal symptoms (watery discharge from the nose, nasal congestion, sneezing and nasal pruritus) and QOL (Short Form-36) were recorded before and after treatment.

Results:

When compared before and after treatment, each group’s total nasal symptom scores reduced significantly (Group A, P = .001; Group B, P = .002), and QOL scores improved significantly (Group A, P = .001, Group B, P = .001). But when compared between groups, Group A results were better than Group B (total nasal symptom scores P = .001, QOL scores P = .003).

Conclusions:

Although intranasal mometasone furoate is a better choice than oral cetirizine, both of these medicines can be used to control allergic rhinitis symptoms and improve patient QOL.